site stats

Gain therapeutics logo

WebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, … WebMar 10, 2024 · Mar 10, 2024 7:32AM EST G ain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, announced terms for its IPO on Wednesday. The Bethesda,...

Gain Therapeutics - Home

WebMar 22, 2024 · Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have … Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target … Gain is utilizing its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) … Parkinson’s disease is a neurodegenerative disorder that affects more than 6 million … Company expects completion of IND-enabling studies of GT-02287 in H1 … GAIN THERAPEUTICS INC. 4800 Montgomery Lane Ste 220 Bethesda, … Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about … Gain is utilizing its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) … International Congress of Parkinson’s Disease and Movement Disorders 2024 … International Congress of Parkinson’s Disease and Movement Disorders 2024 … WebAug 3, 2024 · The market expects Gain Therapeutics, Inc. (GANX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended … pink cereal spoon https://feltonantrim.com

Gain Therapeutics - Brief Introduction

WebNov 11, 2024 · Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Presentations August, 2024 Corporate Presentation WebApr 13, 2024 · Bellerophon Therapeutics (BLPH) closed the most recent trading day at $10.98, moving -1.08% from the previous trading session. This change lagged the S&P 500's daily gain of 1.33%. WebJul 21, 2024 · BETHESDA, Md., July 21, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on developing first-in-class medicines that target novel allosteric binding... pink cereal box

2024-03-29 NDAQ:GANX Press Release Gain Therapeutics Inc.

Category:Gain Therapeutics, Inc. (GANX) - Stock Analysis

Tags:Gain therapeutics logo

Gain therapeutics logo

Gain Therapeutics - Crunchbase Company Profile & Funding

WebMar 23, 2024 · Gain Therapeutics, Inc. is dedicated to the discovery and development of allosteric small molecules therapies for the treatment of neurodegenerative diseases, … WebNov 30, 2024 · In July 2024, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA …

Gain therapeutics logo

Did you know?

WebMar 18, 2024 · BETHESDA, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price ... WebLast Funding Type Series B. Legal Name Gain Therapeutics, Inc. Stock Symbol NASDAQ:GANX. Company Type For Profit. Contact Email [email protected]. …

WebGain Therapeutics is a biotech company developing pharmacological chaperones drugs designed to treat rare metabolic disorders. Bethesda, Maryland, United States 11-50 Series B Public … WebApr 14, 2024 · Seres Therapeutics (MCRB Quick Quote MCRB - Free Report) shares soared 5.8% in the last trading session to close at $6.05. The move was backed by solid volume with far more shares changing hands ...

WebApr 10, 2024 · The MarketWatch News Department was not involved in the creation of this content. Apr 10, 2024 (The Expresswire) -- New "Anaplastic Large Cell Lymphoma Therapeutics Market" research report offers ...

Web2 days ago · About Gain Therapeutics, Inc. Gain Therapeutics, Inc. is a biotechnology company leading the discovery and development of allosteric small molecule therapies. …

WebDec 16, 2024 · General Public Ownership. The general public -- including retail investors -- own 58% of Gain Therapeutics. This size of ownership gives investors from the general … pink cereal charactersWebSep 20, 2024 · Sep 20, 2024 07:46AM EDT (RTTNews) - Biotechnology company Gain Therapeutics, Inc. (GANX) announced Tuesday that Chief Operating Officer Matthias Alder has been appointed as the Company's Chief... pink chablis dead nettleWebApr 5, 2024 · Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. pink certificate borderWebApr 5, 2024 · Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Pleural Effusion – Pipeline Review, H1 2024, provides comprehensive information on the therapeutics under ... pink cereal milk strainWebApr 10, 2024 · Apr 10, 2024 (The Expresswire) -- [102 Insights] “ Anti-tuberculosis Therapeutics Market ” Size 2024 Key players Profiled in the Report are [, Novartis AG, Sun Pharmaceutical Industries, Pfizer... pink cereal bowlsWebAbout us. Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, “SEE ... pink certificate holdersWebApr 12, 2024 · BETHESDA, Md., April 12, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial … pink ceylon sapphire ring